Personalis and the Garvan Institute Announce Commercial Partnership for Whole Human Genome Sequencing, Analysis and Interpretation
Collaboration to Bring Together High-Quality, Large-Scale Whole Genome Sequencing with Best-in-Class Analysis and Interpretation Services for Research and Clinical Applications
October 20, 2014 – Personalis, Inc., a leading genomics-based clinical research and diagnostics global service provider based in the USA, and the Garvan Institute of Medical Research in Sydney, Australia, today announced plans to form a commercial partnership designed to bring together best-in-class solutions for high-quality, large-scale human whole genome sequencing, analysis and interpretation for researchers and clinicians, worldwide.
The Garvan Institute of Medical Research, one of Australia’s leading medical research institutions, created the first purpose-built facility in its country for undertaking large-scale clinical research projects and ultimately clinical-grade genome sequencing for diagnostic purposes.
“We are excited to enter into a partnership that will allow researchers and clinicians worldwide to leverage Garvan’s sophisticated sequencing expertise and large-scale sequencing platforms, and for all parties involved to benefit from Personalis’ sophisticated pipeline, analysis experience, and core infrastructure capabilities that have been expertly honed through the analysis of thousands of human genomes,” said John West, Chief Executive Officer at Personalis. “Whole human genome sequencing analysis can be daunting, complex and time-consuming. This agreement will accelerate the pace of scientific research and clinical diagnosis by facilitating rapid, comprehensive and accurate whole genome sequencing combined with high-quality analysis and easy-to-interpret reports for large projects involving human data.”
Associate Professor Marcel Dinger, Head of the Kinghorn Centre for Clinical Genomics at the Garvan Institute, added: “The expertise at Personalis in analyzing, annotating and interpreting human genome sequencing data and in designing human genome research studies for clinical diagnostics is first-class, and we are delighted to combine our world-class facilities in a way that will benefit researchers and clinicians worldwide.”
Leadership from both organizations are present to discuss their individual and combined solutions at the 2014 American Society of Human Genetics Annual Meeting, which is now underway in San Diego. For more information about the meeting visit http://www.ashg.org/2014meeting.
About the Garvan Institute for Medical Research
The Garvan Institute of Medical Research was founded in 1963 and is now one of Australia’s largest medical research institutions with over 600 scientists, students and support staff. Garvan’s main research areas are: Cancer, Diabetes & Metabolism, Immunology and Inflammation, Osteoporosis and Bone Biology, and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease. In 2012, Garvan established Australia’s first purpose-built facility for undertaking large-scale genome sequencing projects. The Kinghorn Centre for Clinical Genomics (KCCG) researchers undertake collaborative projects and genome-based studies to improve genome interpretation, with the ultimate aim of advancing the use of genomic information in patient care. KCCG is seeking accreditation that would ultimately allow clinicians to sequence genomes for diagnostic and therapeutic purposes.
- Media Contact for Garvan Institute:
- Alison Heather
- Science Communications Manager
- T: +61 (0) 2 9295 8128; M: +61 (0) 434 071 326
- E: email@example.com